Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

PAM-HC: A Bayesian Nonparametric Construction of Hybrid Control for Randomized Clinical Trials Using External Data

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Adaptive Hybrid Control Design for Comparative Clinical Trials with Historical Control Data

Case weighted power priors for hybrid control analyses with time-to-event data

A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling

Bayesian Nonparametric Common Atoms Regression for Generating Synthetic Controls in Clinical Trials

Incorporating External Data into the Analysis of Clinical Trials via Bayesian Additive Regression Trees

A randomized trial of pneumatic reduction versus hydrostatic reduction for intussusception in pediatric patients.

A Bayesian Hybrid Design with Borrowing from Historical Study

Optimal Bayesian Hierarchical Model to Accelerate the Development of Tissue-Agnostic Drugs and Basket Trials.

Deep historical borrowing framework to prospectively and simultaneously synthesize control information in confirmatory clinical trials with multiple endpoints

A Bayesian Response-Adaptive Covariate-Balanced Randomization Design with Application to A Leukemia Clinical Trial

BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints

A matching design for augmenting a randomized clinical trial with external control

Matching within a hybrid RCT/RWD: framework on associated causal estimands

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

Integrating Randomized Placebo-Controlled Trial Data with External Controls: A Semiparametric Approach with Selective Borrowing

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

Digital twins and Bayesian dynamic borrowing: Two recent approaches for incorporating historical control data

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Evaluating hybrid controls methodology in early-phase oncology trials: a simulation study based on the MORPHEUS-UC trial